Itruvone

Itruvone
Clinical data
Other names	PH10; PH10A; PH10 NS; Pregn-4-en-20-yn-3-one
Routes of; administration	Intranasal (spray)
Identifiers
	IUPAC name (8S,9S,10R,13S,14S,17R)-17-ethynyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one;
CAS Number	21321-89-1;
PubChem CID	15633961;
ChemSpider	18829396;
UNII	72HML2UK6J;
KEGG	D12542;
Chemical and physical data
Formula	C21H28O
Molar mass	296.454 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C#C)CCC4=CC(=O)CC[C@]34C;
	InChI InChI=1S/C21H28O/c1-4-14-6-8-18-17-7-5-15-13-16(22)9-11-21(15,3)19(17)10-12-20(14,18)2/h1,13-14,17-19H,5-12H2,2-3H3/t14-,17-,18-,19-,20+,21-/m0/s1; Key:CHOUAXDNNAVGHR-NWSAAYAGSA-N;

Itruvone (INNTooltip International Nonproprietary Name; developmental code name PH10), also known as pregn-4-en-20-yn-3-one, is a vomeropherine which is under development by VistaGen Therapeutics as a nasal spray for the treatment of major depressive disorder.^[1]^[2]^[3]^[4]^[5]^[6]

References

^ "PH-10 Nasal Spray". AdisInsight. Springer Nature Switzerland AG.
^ Monti L, Liebowitz MR (February 2022). "Neural circuits of anxiolytic and antidepressant pherine molecules". CNS Spectr. 27 (1): 66–72. doi:10.1017/S109285292000190X. PMID 33092667. S2CID 225053518.
^ "VistaGen Therapeutics Acquires Worldwide Rights to Develop and Commercialize PH10, a First-in-Class Intranasally Administered Neuroactive Steroid with Rapid-onset Antidepressant Effects for Major Depressive Disorder Demonstrated in Phase 2a Study :: VistaGen Therapeutics, Inc. (VTGN)". VistaGen Therapeutics, Inc. Retrieved 2019-12-19.
^ "Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more". www.bizjournals.com. San Francisco Business Times. October 29, 2018. Retrieved 20 July 2020.
^ Liebowitz MR, Nicolini H, Monti L, Hanover R (2013). PH 10 may be a new rapidly acting intranasally administered antidepressant. Vol. American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, Miami, FL.
^ Jancin B (2013). "Novel intranasal antidepressant shows results after 1 week". Clinical Psychiatry News. Retrieved 13 January 2016.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[AdisInsight-1] "PH-10 Nasal Spray". AdisInsight. Springer Nature Switzerland AG.

[pmid33092667-2] Monti L, Liebowitz MR (February 2022). "Neural circuits of anxiolytic and antidepressant pherine molecules". CNS Spectr. 27 (1): 66–72. doi:10.1017/S109285292000190X. PMID 33092667. S2CID 225053518.

[3] "VistaGen Therapeutics Acquires Worldwide Rights to Develop and Commercialize PH10, a First-in-Class Intranasally Administered Neuroactive Steroid with Rapid-onset Antidepressant Effects for Major Depressive Disorder Demonstrated in Phase 2a Study :: VistaGen Therapeutics, Inc. (VTGN)". VistaGen Therapeutics, Inc. Retrieved 2019-12-19.

[4] "Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more". www.bizjournals.com. San Francisco Business Times. October 29, 2018. Retrieved 20 July 2020.

[Liebowitz2013-5] Liebowitz MR, Nicolini H, Monti L, Hanover R (2013). PH 10 may be a new rapidly acting intranasally administered antidepressant. Vol. American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, Miami, FL.

[Jancin2013-6] Jancin B (2013). "Novel intranasal antidepressant shows results after 1 week". Clinical Psychiatry News. Retrieved 13 January 2016.

[1]

[2]

[3]

[4]

[5]

[6]

See also

References